EUROPEAN COMMISSION APPROVES KEPIVANCE (PALIFERMIN) FOR ORAL MUCOSITIS IN CANCER PATIENTS

Amgen, the world's largest biotechnology company, today announced that Kepivance(TM) (palifermin) has received regulatory approval in the European Union (EU). Palifermin is now authorized in the EU to decrease the incidence, duration and severity of oral mucositis (mouth sores) in patients with hematologic (blood) cancers undergoing myeloablative therapy associated with a high incidence of severe oral mucositis, and requiring autologous blood and bone marrow transplant. In the EU, approximately 13,000 cancer patients undergo autologous blood and bone marrow transplant each year.

Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=1091450XSL_NEWSML_TO_NEWSML_WEB.xml)